Continental Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.51M | Sell |
125,000
-120,000
| -49% | -$3.19M | 1.79% | 23 |
|
|
2025
Q4 | $6.1M | Sell |
245,000
-36,000
| -13% | -$908K | 2.58% | 12 |
|
|
2025
Q3 | $7.16M | Sell |
281,000
-66,000
| -19% | -$1.63M | 3.1% | 10 |
|
|
2025
Q2 | $8.41M | Buy |
347,000
+87,000
| +33% | +$2.03M | 3.94% | 6 |
|
|
2025
Q1 | $6.59M | Sell |
260,000
-50,000
| -16% | -$1.31M | 3.69% | 9 |
|
|
2024
Q4 | $8.22M | Buy |
310,000
+110,000
| +55% | +$2.98M | 3.79% | 5 |
|
|
2024
Q3 | $5.79M | Sell |
200,000
-120,000
| -38% | -$3.5M | 2.79% | 12 |
|
|
2024
Q2 | $8.95M | Sell |
320,000
-60,000
| -16% | -$1.65M | 3.93% | 2 |
|
|
2024
Q1 | $10.5M | Sell |
380,000
-49,900
| -12% | -$1.38M | 4.26% | 3 |
|
|
2023
Q4 | $12.4M | Buy |
429,900
+43,100
| +11% | +$1.3M | 4.83% | 3 |
|
|
2023
Q3 | $12.8M | Buy |
386,800
+74,400
| +24% | +$2.63M | 6.83% | 2 |
|
|
2023
Q2 | $11.5M | Buy |
312,400
+156,900
| +101% | +$6.11M | 5.18% | 2 |
|
|
2023
Q1 | $6.34M | Buy |
155,500
+105,500
| +211% | +$4.56M | 3.39% | 9 |
|
|
2022
Q4 | $2.56M | Buy |
50,000
+100
| +0.2% | +$4.79K | 1.34% | 29 |
|
|
2022
Q3 | $2.18M | Buy |
49,900
+19,900
| +66% | +$967K | 1.29% | 34 |
|
|
2022
Q2 | $1.57M | Hold |
30,000
| – | – | 0.95% | 40 |
|
|
2022
Q1 | $1.55M | Sell |
30,000
-30,000
| -50% | -$1.56M | 0.77% | 39 |
|
|
2021
Q4 | $3.54M | Sell |
60,000
-45,000
| -43% | -$2.23M | 1.49% | 24 |
|
|
2021
Q3 | $4.52M | Buy |
+105,000
| New | +$4.65M | 1.92% | 19 |
|
|
2021
Q2 | – | Sell |
-149,600
| Closed | -$5.42M | – | 66 |
|
|
2021
Q1 | $5.42M | Buy |
149,600
+98,600
| +193% | +$3.5M | 2.51% | 11 |
|
|
2020
Q4 | $1.88M | Sell |
51,000
-1,700
| -3% | -$62.4K | 0.86% | 48 |
|
|
2020
Q3 | $1.83M | Sell |
52,700
-10,540
| -17% | -$370K | 0.97% | 43 |
|
|
2020
Q2 | $1.96M | Buy |
63,240
+31,620
| +100% | +$1.07M | 1.05% | 42 |
|
|
2020
Q1 | $979K | Buy |
+31,620
| New | +$1.08M | 0.73% | 55 |
|
|
2016
Q2 | – | Sell |
-10,540
| Closed | -$296K | – | 134 |
|
|
2016
Q1 | $296K | Buy |
+10,540
| New | +$301K | 0.08% | 123 |
|
|
2015
Q2 | – | Sell |
-47,430
| Closed | -$1.57M | – | 150 |
|
|
2015
Q1 | $1.57M | Sell |
47,430
-31,620
| -40% | -$1.01M | 0.35% | 88 |
|
|
2014
Q4 | $2.34M | Buy |
+79,050
| New | +$2.27M | 0.47% | 68 |
|
Other funds holding PFE
VCM
VPM
Continental Advisors's PFE Position: Q1 2026 in Review
Continental Advisors reduced its Pfizer (PFE) stake by 3.6% in Q1 2026, selling an estimated $386K and leaving 386,438 shares worth $10.9M. The position accounts for 5.54% of the portfolio, ranked #4.
Continental Advisors first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Continental Advisors held 386,438 shares of Pfizer worth $10.9M as of Q1 2026.
- Continental Advisors sold 14,500 Pfizer shares in Q1 2026, an estimated $386K.
- Pfizer made up 5.54% of Continental Advisors's portfolio in Q1 2026, its #4 holding.
- Continental Advisors first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Continental Advisors's 13F filing for Q1 2026, filed 15 May 2026.